[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preeclampsia-pe-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preeclampsia-pe-risk":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,60,89,118,139,167,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441",false,"NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators","FEMALE","18 Years","45 Years",{"count":21,"type":22},50,"ESTIMATED","9 Months","OBSERVATIONAL","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[27,28,29,30,31,32,33,34,35,36,37,38],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Cardiometabolic Diseases","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[40,41,27,31,42,43,44,45,46],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","RECRUITING","2026-04-27",{"date":50,"type":51},"2026-05-04","ACTUAL",{"date":53,"type":51},"2025-12-10",{"date":55,"type":22},"2027-08",{"name":57,"class":58},"University of Tennessee Graduate School of Medicine","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100629796","estimated-risk-of-preeclampsia-in-the-first-trimester-and-its-association-with-subclinical-atherosclerosis-and-cardiovascular-risk-in-women-with-type-1-diabetes-100629796","NCT07479329","Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes","PREEATH-T1D","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of type 1 diabetes\n* At least one prior pregnancy with first-trimester preeclampsia screening (\\\u003C14 weeks gestation)\n* ≥3 years since last pregnancy\n\nExclusion Criteria:\n\n* Previous multiple pregnancy\n* Cardiovascular disease before pregnancy (coronary heart disease, stroke\u002FTIA, peripheral artery disease, heart failure)\n* Active pregnancy at time of evaluation\n* Alcohol or substance dependence (except nicotine\u002Fcaffeine) in the last 3 years\n* Active severe psychiatric disease, dementia, severe disability, or reduced life expectancy",{"count":68,"type":22},1300,"This multicenter observational cohort study aims to evaluate whether estimated first-trimester risk of preeclampsia (PE) is associated with subclinical atherosclerosis, cardiovascular risk profile, and cardiovascular events in women with type 1 diabetes (T1D) at least 3 years after pregnancy.\n\nWomen with T1D and at least one prior pregnancy with documented first-trimester PE screening will be classified as high or low PE risk according to validated multivariable algorithms. The presence of carotid plaques, cardiometabolic risk factors, and incident cardiovascular events will be assessed during a study visit.",[71,27,30],"Type 1 Diabetes",[71,27,73,74,75,76,77],"Preeclampsia Risk","Preclinical carotid atherosclerosis","Carotid ultrasonography","Cardiovascular risk","Cardiovascular disease","NOT_YET_RECRUITING","2026-03-16",{"date":81,"type":51},"2026-03-18",{"date":83,"type":22},"2026-04-10",{"date":85,"type":22},"2028-04-30",{"name":87,"class":58},"Institut d'Investigacions Biomèdiques August Pi i Sunyer",2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":59},"100628612","a-study-to-find-and-confirm-blood-based-markers-called-proteins-that-may-show-early-heart-changes-in-women-with-preeclampsia-even-before-symptoms-appear-and-the-use-of-heart-ultrasound-echocardiography-to-look-at-patterns-of-how-the-heart-changes-during-pregnancy-in-women-with-preeclampsia-100628612","NCT07463898","A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia.","PRoteomics and EchoCardiography for Identifying Subclinical Cardiac Dysfunction in Preeclampsia (PRECISE)","PRECISE","Inclusion Criteria:\n\n* • Pregnant women who are up to 20 weeks pregnant\n\n  * Able to consent to participate in the study\n  * Are enrolled in the ENHANCE-CVH study\n  * Willing to undergo echocardiography and blood draws\n\nExclusion Criteria:\n\n* • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \\[CAD\\])\n\n  * Sickle cell disease\n  * Pulmonary arterial hypertension\n  * Pulmonary embolism\n  * Inability to provide informed consent\n  * Acute Illness\n  * Malignancy",true,"13 Years","50 Years",{"count":101,"type":22},172,"The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are:\n\n* Do these blood markers relate to heart changes on ultrasound?\n* How may they help predict future health problems for the mother?\n\nParticipants will:\n\n* Complete a 20-minute survey that will include taking your baseline demographic information, clinical information\u002Fmedical history, asking about pre-existing health conditions, including measuring your height, weight, and blood pressure.\n* Have transthoracic echocardiography (TTE) performed at 12 - 16 weeks gestation and again at 28 - 32 weeks gestation.\n* Provide a blood sample for these protein measurements. These samples will be collected at intake (12 - 16 weeks gestation) and again at 28 - 32 weeks gestation.",[104,30,29],"Cardiovascular Biomarkers",[106,107,108],"cardiac phenotypes","preeclampsia","cardiovascular biomarkers","2026-03-05",{"date":111,"type":51},"2026-03-11",{"date":113,"type":22},"2026-03",{"date":115,"type":22},"2027-12",{"name":117,"class":58},"Washington University School of Medicine",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100606676","preeclampsia-and-defective-placentation-in-oocyte-donation-importance-of-hla-c-and-kir-100606676","NCT07178652","Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR","IMMUN-OR","Inclusion Criteria:\n\n* Every live birth delivery post oocyte donation (mother, child, donor).\n\nExclusion Criteria:\n\n* Unknown HLA-C\u002FKIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.",{"count":126,"type":22},2325,"The IMMUN-OR study aims to study HLA-C\u002FKIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C\u002FKIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C\u002FKIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C\u002FKIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.",[30,129],"Oocyte Donation","2025-09-10",{"date":132,"type":51},"2025-09-17",{"date":134,"type":22},"2025-09",{"date":136,"type":22},"2029-08",{"name":138,"class":58},"Universitair Ziekenhuis Brussel",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":59},"100577789","relationship-between-aspirin-metabolism-and-markers-of-metabolic-dysfunction-among-pregnant-persons-at-risk-of-pre-eclampsia-100577789","NCT06802861","Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia","RAMP","Inclusion Criteria:\n\n* Recommended aspirin for pre-eclampsia prevention by OB\u002FGYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)\n\n  * Willingness to adhere to aspirin therapy\n  * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n  * Gestational age at enrollment \\\u003C16 weeks\n  * Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n\n  * Type 1 Diabetes Mellitus\n  * Current gestational diabetes mellitus\n  * Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n  * Thrombophilia\n  * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n  * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n  * Current or recent use of steroids\n  * Current use of prophylactic or therapeutic anticoagulation\n  * Medical contraindication to aspirin therapy\n  * Molar pregnancy\n  * Renal disease\n  * Inability or unwillingness to give informed consent\n  * Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":21,"type":22},"This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.",[27,29,30,149,36,37,31,32,38],"Obesity and Obesity-related Medical Conditions",[151,152,153,154,155,156,157,158,159],"metabolic dysfunction","gestational diabetes","pregnancy","maternal obesity","maternal insulin resistance","aspirin metabolism","GDM","substrate oxidation","gestational glucose intolerance","2025-09-03",{"date":130,"type":51},{"date":163,"type":51},"2025-01-01",{"date":165,"type":22},"2028-12-31",{"name":57,"class":58},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":59},"100601115","hyperspectral-imaging-for-prediction-of-preeclampsia-100601115","NCT07106294","Hyperspectral Imaging for Prediction of Preeclampsia","Systematic Evaluation of Hyperspectral Analysis as a Predictive Marker of Preeclampsia","HIPPA","Inclusion Criteria:\n\n* singleton pregnancies\n* age ≥ 18 years\n* patient's ability to provide consent\n* written informed consent\n* women scheduled for a routine ultrasound scan in first or second trimester\n\nExclusion Criteria:\n\n* lack of consent\n* language barrier\n* severe fetal chromosomal\u002Fgenetic\u002Fstructural anomalies known at study enrollment\n* smoking in the last two hours before measurement\n* diagnosis of preeclampsia at study enrollment",{"count":176,"type":22},1430,"Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia.\n\nHyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia.\n\nThe HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.",[30,27],[107,180,181,182],"hyperspectral imaging","EASIX","endothelial dysfunction","2025-08-24",{"date":185,"type":51},"2025-08-29",{"date":187,"type":51},"2025-08-21",{"date":189,"type":22},"2027-07-01",{"name":191,"class":58},"Heidelberg University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":199,"targetDuration":4,"studyType":201,"phases":202,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":59},"100574458","an-interventional-pilot-study-on-the-effect-of-extra-virgin-olive-oil-on-women-with-preeclampsia-risk-100574458","NCT06759545","An Interventional Pilot Study on the Effect of Extra Virgin Olive Oil on Women with Preeclampsia Risk","Effect of Extra Virgin Olive Oil Addition in the Diet of Women with Higher Risk for Preeclampsia - Interventional Pilot Study","Inclusion Criteria:\n\n* Pregnant women with clinical risk factors for PE \\[previous PE, primigravida, chronic hypertension, chronic renal disease, autoimmune disease (systemic lupus erythematosus, antiphospholipid antibody syndrome), overweight (BMI\\>30), obesity (BMI\\>35), morbid obesity (BMI\\>40), presentational diabetes (type 1 or type 2), multiple pregnancy\\].\n* gestational ages of 8 to 16 weeks attending Barzilai University Medical Center at Ashkelon (BUMCA).\n\nExclusion Criteria:\n\n• Refusing enrollment or participation.",{"count":200,"type":22},156,"INTERVENTIONAL",[203],"NA","This study explores the potential benefits of Extra Virgin Olive Oil from early harvested olives (EVOOEH) in reducing the risk of preeclampsia (PE) in high-risk pregnant women. EVOO, particularly EVOOEH, is rich in antioxidant compounds, including polyphenols, which may help improve vascular health and reduce oxidative stress, potentially preventing complications like PE. The hypothesis is that EVOOEH may reduce microvascular damage, improve placentation, and prevent dysglycemia, ultimately lowering the risk of PE and gestational diabetes mellitus (GDM).\n\nThe primary objective of this intervention is to evaluate the effect of EVOOEH on PE incidence during pregnancy, specifically assessing the impact on markers of PE, GDM, and other pregnancy-related outcomes. The study is designed as an interventional, randomized, parallel-assignment dietary trial involving 156 pregnant women at high risk for PE, aged 18 to 45. Participants will receive either a daily dose of 42 ml (three tablespoons) of EVOOEH or the Ministry of Health (MOH) general dietary recommendations for pregnancy for four weeks, starting between 8 to 16 weeks of gestation.\n\nThe study arms are as follows:\n\nEVOOEH arm: Participants will consume 42 ml of EVOOEH daily along with MOH dietary recommendations for four weeks (n=78).\n\nControl arm: Participants will follow only the MOH dietary recommendations for four weeks (n=78).\n\nThe intervention will occur alongside low-dose aspirin prophylaxis for PE prevention, as recommended by guidelines for women at high risk. Key compliance markers include adherence to a Mediterranean diet as measured by the Mediterranean Diet Adherence Screener (MEDASIS) and hydroxytyrosol levels in maternal blood. The study will mask data analysis to minimize bias.\n\nThe primary outcome measures are maternal glucose challenge test (GCT) results and the serum soluble FMS-like tyrosine kinase 1\u002Fplacental growth factor (sFlt-1\u002FPlGF) ratio at the end of the intervention. Secondary outcomes include the incidence of GDM, PE, cesarean sections, preterm delivery, small for gestational age (SGA) births, blood pressure measurements, gestational age at delivery, and any relevant data available from participants' medical records.\n\nEligibility criteria include pregnant women with risk factors for PE such as a history of PE, chronic hypertension, obesity, or diabetes, among others, and a gestational age between 8 to 16 weeks. Exclusion criteria involve low-risk pregnancies or women who refuse participation.\n\nBlood samples will be collected to assess 25-hydroxyvitamin D (25(OH)D), hydroxytyrosol (HT), and the sFlt-1\u002FPlGF ratio. Laboratory analyses will be conducted at Barzilai University Medical Center and the Weizmann Institute of Science. This study seeks to determine whether EVOOEH's higher polyphenol content compared to standard EVOO can offer additional protective benefits against PE and related complications in high-risk pregnancies.",[30],[207,107,208,209,210,211,212],"Extra virgin olive oil from early harvested olives","FMS-like tyrosine kinase 1","plasma hydroxytyrosol","dietary intervention","point Mediterranean Diet Adherence Screener","prevention","2025-02-04",{"date":215,"type":51},"2025-02-06",{"date":217,"type":51},"2025-01-28",{"date":219,"type":22},"2028-01-07",{"name":221,"class":58},"Yaniv Ovadia"]